SCHEMBL16654071

SCHEMBL16654071

CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)c(N)c2)CC1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 17/20 0.79
FGFR4 P22455 9/20 0.79
FGFR3 P22607 6/20 0.79
FGFR2 P21802 5/20 0.79
JAK2 O60674 2/20 0.79
ABL1 P00519 2/20 0.79
INSR P06213 2/20 0.79
LCK P06239 2/20 0.79
FYN P06241 2/20 0.79
YES1 P07947 2/20 0.79
LYN P07948 2/20 0.79
RET P07949 2/20 0.79
MET P08581 2/20 0.79
ROS1 P08922 2/20 0.79
KIT P10721 2/20 0.79
SRC P12931 2/20 0.79
BRAF P15056 2/20 0.79
PDGFRA P16234 2/20 0.79
FLT1 P17948 2/20 0.79
TYK2 P29597 2/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18162329 0.94 FGFR1 (0.71) FGFR1FGFR4FGFR3FGFR2JAK2
SCHEMBL2014816 0.93 FGFR1 (0.83) FGFR1FGFR4FGFR3FGFR2JAK2
SCHEMBL2014529 0.92 FGFR1 (0.81) FGFR1FGFR4FGFR3FGFR2JAK2
SCHEMBL2012965 0.91 FGFR1 (0.79) FGFR1FGFR4FGFR3FGFR2JAK2
SCHEMBL22171996 0.90 FGFR4 (0.84) FGFR1FGFR4FGFR3FGFR2JAK2
SCHEMBL18153617 0.90 FGFR1 (0.77) FGFR1FGFR4FGFR3FGFR2JAK2
SCHEMBL16665231 0.89 FGFR1 (0.76) FGFR1FGFR4FGFR3FGFR2JAK2
SCHEMBL16665219 0.89 FGFR1 (0.80) FGFR1FGFR4FGFR3FGFR2JAK2
SCHEMBL16656075 0.88 FGFR1 (0.75) FGFR1FGFR4FGFR3FGFR2JAK2
Infigratinib SCHEMBL374435 0.88 FGFR3 (1.00) FGFR1FGFR4FGFR3FGFR2JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11498916-B2 Crystalline FGFR4 inhibitor compound and uses thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2022-11-15 US disclosed
CN-107660200-B Crystalline FGFR4 inhibitor compounds and uses thereof 卫材R&D管理有限公司 2022-01-11 CN disclosed
EP-3421457-B1 PYRIMIDINE FGFR4 INHIBITORS EISAI R&D MAN CO LTD (JP) 2021-10-06 EP disclosed
EP-3421457-B1 PYRIMIDINE FGFR4 INHIBITORS EISAI R&D MAN CO LTD (JP) 2021-10-06 EP disclosed
US-10912774-B2 Pyrimidine FGFR4 inhibitors EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-02-09 US disclosed
US-10912774-B2 Pyrimidine FGFR4 inhibitors EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-02-09 US disclosed
EP-3283465-B1 CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF EISAI R&D MAN CO LTD (JP) 2021-01-06 EP disclosed
EP-3283465-B1 CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF EISAI R&D MAN CO LTD (JP) 2021-01-06 EP disclosed
US-20200317645-A1 CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF EISAI R&D MANAGEMENT CO., LTD. (JP) 2020-10-08 US disclosed
US-20200317645-A1 CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF EISAI R&D MANAGEMENT CO., LTD. (JP) 2020-10-08 US disclosed
WO-2016168331-A1 CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-10-20 WO disclosed
US-9434697-B2 Pyrimidine FGFR4 inhibitors EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-09-06 US disclosed
US-9434697-B2 Pyrimidine FGFR4 inhibitors EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-09-06 US disclosed
EP-3057943-A1 PYRIMIDINE FGFR4 INHIBITORS Eisai R&D Management Co., Ltd. (JP) 2016-08-24 EP disclosed
US-20160130237-A1 PYRIMIDINE FGFR4 INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-05-12 US disclosed
US-20160130237-A1 PYRIMIDINE FGFR4 INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-05-12 US disclosed
WO-2015057963-A1 FGFR4 INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-23 WO disclosed
WO-2015057938-A1 PYRIMIDINE FGFR4 INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-23 WO disclosed
WO-2015057938-A1 PYRIMIDINE FGFR4 INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-23 WO disclosed
WO-2015057963-A1 FGFR4 INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11498916-B2 Crystalline FGFR4 inhibitor compound and uses thereof FGFR4, FGFR1, FGFR3 FGFR1 2/4885FGFR4 1/4885FGFR3 3/4885
US-10912774-B2 Pyrimidine FGFR4 inhibitors FGFR4, FGFR1, FGFR3 FGFR1 2/4885FGFR4 1/4885FGFR3 3/4885
US-20160130237-A1 PYRIMIDINE FGFR4 INHIBITORS FGFR4, FGFR1, FGFR3 FGFR1 2/4885FGFR4 1/4885FGFR3 3/4885
US-20200317645-A1 CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF FGFR4, FGFR1, FGFR3 FGFR1 2/4885FGFR4 1/4885FGFR3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.